Drug Profile
Research programme: liver disease diagnostic imaging and therapeutics - Takeda Pharmaceutical Company/GE Healthcare
Latest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator GE Healthcare; Takeda
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis; Liver disorders
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for research development in Hepatic-fibrosis(Diagnosis) in Japan
- 28 Dec 2018 No recent reports of development identified for research development in Hepatic-fibrosis(Diagnosis) in United Kingdom
- 28 Dec 2018 No recent reports of development identified for research development in Liver-disorders in Japan